Journal: Oncogene
This study assesses the clinical impact of whole genome sequencing (WGS) in 96 metastatic colorectal cancer (mCRC) patients.
Key findings include:
- WGS identified clinically actionable biomarkers in 81% of cases, with nearly half of these biomarkers undetected by standard diagnostic methods.
- The incorporation of WGS increased biomarker-driven treatment from 11% to at least 24% of patients.
- Patient-derived organoids (PDOs) were used to functionally validate drug sensitivity to targeted therapies, confirming differential responses based on genomic findings.
The results support WGS as a valuable tool for expanding personalized treatment options in mCRC. Additionally, PDO pre-screening enhances therapeutic precision by identifying effective patient-specific interventions.